RESUMO
Atorvastatin calcium (AC) is a second-generation 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor approved for clinical use as a lipid lowering agent. AC, the world's best selling drug is associated with poor oral bioavailability and serious adverse effects like rhabdomyolysis on chronic administration. A biodegradable nanoparticulate approach was introduced here with a view to improving the efficacy and safety of AC. Poly lactide-co-glycolic acid (PLGA) nanoparticles containing atorvastatin calcium were prepared using two stabilizers i.e. didodecyl dimethyl ammonium bromide (DMAB) and Vitamin E tocopheryl polyethylene glycol 1000 succinate (Vit E-TPGS) using a co-solvent approach by emulsion-diffusion-evaporation method. AC loaded PLGA nanoparticles prepared using DMAB and Vit E-TPGS were found to be 120.0 +/- 4.2 nm and 140.0 +/- 1.5 nm (z-average) in size respectively. In vitro release studies at pH 7.4 revealed a zero order release profile for nanoparticles. Efficacy and safety parameters of the prepared nanoparticles against marketed formulation were evaluated in high fat diet fed (hyperlipidemic) rats. It was found that atorvastatin calcium nanoparticles were equally effective in comparison to Lipicure, at a 66%-reduced dose in treating the hyperlipidemia characterized by alterations in PTC, LDL-C, VLDL-C, HDL-C, PTG and PGL in the high fat diet fed rats. On the other hand, when evaluated for safety, nanoparticulate formulation showed no/negligible myotoxicity characterized by lower PC, BUN, CK, LDH and AST levels in comparison to the marketed formulation.
Assuntos
Anticolesterolemiantes/administração & dosagem , Ácidos Heptanoicos/administração & dosagem , Hiperlipidemias/tratamento farmacológico , Nanopartículas/administração & dosagem , Pirróis/administração & dosagem , Administração Oral , Animais , Anticolesterolemiantes/farmacocinética , Anticolesterolemiantes/uso terapêutico , Anticolesterolemiantes/toxicidade , Atorvastatina , Glicemia/análise , Colesterol/sangue , Modelos Animais de Doenças , Ácidos Heptanoicos/farmacocinética , Ácidos Heptanoicos/uso terapêutico , Ácidos Heptanoicos/toxicidade , Hidroximetilglutaril-CoA Redutases/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/toxicidade , Hiperlipidemias/induzido quimicamente , Hiperlipidemias/enzimologia , Ácido Láctico , Lipídeos/sangue , Masculino , Ácido Poliglicólico , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Pirróis/farmacocinética , Pirróis/uso terapêutico , Pirróis/toxicidade , Ratos , Ratos Sprague-DawleyRESUMO
The present study was carried out to design a viable and practically effective transdermal systems of indomethacin using cream-based drug reservoirs and suitable rate controlling membranes. As vehicles, a more lipophilic base (F(1)) and a cream formulation containing predominant aqueous phase (F(2)) were chosen to study the influence of vehicle nature and role of permeation enhancers that increases thermodynamic activity and to provide diffusible species of drug to skin. Rate controlling membranes of cellulose acetate (CA) and ethyl cellulose (EC) with polyvinyl pyrollidine and hydroxypropyl methyl cellulose were used to design transdermal devices. In vivo, effective plasma concentrations of indomethacin are maintained up to 24 hr whereas oral formulation showed only up to 8 hr. Although the plasma drug levels between both EC films differ insignificantly, PVP film showed a better pharmacokinetic profile. The pharmacodynamic performance of the transdermal devices exhibited good anti-inflammatory activity over 24 hr compared with orally administered indomethacin. In vivo studies indicate the superiority of CA films over the EC films. Further, enhancement may be achieved with other classic enhancers/enhancement strategies with such devices containing aqueous cream vehicle and the optimum membranes.
Assuntos
Preparações de Ação Retardada/síntese química , Indometacina/administração & dosagem , Membranas Artificiais , Administração Cutânea , Administração Oral , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/farmacocinética , Área Sob a Curva , Celulose/análogos & derivados , Celulose/química , Preparações de Ação Retardada/farmacocinética , Preparações de Ação Retardada/farmacologia , Sistemas de Liberação de Medicamentos/métodos , Edema/induzido quimicamente , Edema/tratamento farmacológico , Edema/prevenção & controle , Emulsões/química , Derivados da Hipromelose , Técnicas In Vitro , Indometacina/efeitos adversos , Indometacina/farmacocinética , Masculino , Metilcelulose/análogos & derivados , Metilcelulose/química , Polivinil/química , Pirrolidinas/química , Ratos , Ratos Wistar , Pele/metabolismo , Absorção Cutânea , Úlcera Gástrica/induzido quimicamenteRESUMO
The purpose of this study was the in vivo evaluation of orally and transdermally administered propranolol hydrochloride in rabbits. Transdermal patches of propranolol hydrochloride (PPN) were formulated employing ethyl cellulose and polyvinylpyrrolidone as film formers. The pharmacodynamic (PD) and pharmacokinetic (PK) performance of PPN following transdermal administration was compared with that of oral administration. This study was carried out in a randomized cross-over design in male New Zealand albino rabbits. The PK parameters such as maximum plasma concentration (C(max)), time for peak plasma concentration (t(max)), mean residence time (MRT) and area under the curve (AUC(0-alpha)) were significantly (P<0.01) different following transdermal administration compared to oral administration. The terminal elimination half-life (t(1/2)) of transdermally delivered PPN was found to be similar to that following oral administration. In contrast to oral delivery, a sustained therapeutic activity was observed over a period of 24 h after transdermal administration compared to oral administration. The relative bioavailability of PPN was increased about fivefold to sixfold after transdermal administration as compared to oral delivery. This may be due to the avoidance of first pass effect of PPN. The sustained therapeutic activity was due to the controlled release of drug into systemic circulation following transdermal administration.